Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
02/05/2024 | 13:30 | GlobeNewswire Inc. | Biogen Reports Progress on Corporate Responsibility Priorities | NASDAQ:BIIB | Biogen Inc |
01/04/2024 | 01:30 | PR Newswire (US) | Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA | NASDAQ:BIIB | Biogen Inc |
06/03/2024 | 13:30 | GlobeNewswire Inc. | New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy | NASDAQ:BIIB | Biogen Inc |
04/03/2024 | 22:15 | GlobeNewswire Inc. | Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting | NASDAQ:BIIB | Biogen Inc |
27/02/2024 | 01:54 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:BIIB | Biogen Inc |
23/02/2024 | 13:00 | GlobeNewswire Inc. | Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP | NASDAQ:BIIB | Biogen Inc |
22/02/2024 | 16:12 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:BIIB | Biogen Inc |
13/02/2024 | 13:07 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:BIIB | Biogen Inc |
13/02/2024 | 01:11 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:BIIB | Biogen Inc |
12/02/2024 | 22:06 | GlobeNewswire Inc. | Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia | NASDAQ:BIIB | Biogen Inc |
09/01/2024 | 23:52 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:BIIB | Biogen Inc |
19/12/2023 | 13:30 | GlobeNewswire Inc. | Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European Commission | NASDAQ:BIIB | Biogen Inc |
15/12/2023 | 15:05 | GlobeNewswire Inc. | CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia, a Rare Neurodegenerative Disease | NASDAQ:BIIB | Biogen Inc |
14/12/2023 | 12:30 | Business Wire | ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S. | NASDAQ:BIIB | Biogen Inc |
08/11/2023 | 22:35 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:BIIB | Biogen Inc |
08/11/2023 | 14:19 | IH Market News | Keep An Eye Out: Pre-Market Movers And Analyst Recommendations | NASDAQ:BIIB | Biogen Inc |
06/11/2023 | 23:44 | KR Market News | 월스트리트 상승, 시장은 연준 연사 및 재무부 경매 주목 | NASDAQ:BIIB | Biogen Inc |
06/11/2023 | 13:30 | GlobeNewswire Inc. | Biogen Appoints Monish Patolawala to its Board of Directors | NASDAQ:BIIB | Biogen Inc |
26/10/2023 | 13:08 | IH Market News | Thursday’s Wall Street Highlights: Ford, Morgan Stanley, Align Technology, Endeavor, and more | NASDAQ:BIIB | Biogen Inc |
25/10/2023 | 23:26 | GlobeNewswire Inc. | Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimer’s Disease From Additional Analyses of Clarity AD at The Clinical Trials On Alz | NASDAQ:BIIB | Biogen Inc |
25/10/2023 | 23:25 | PR Newswire (US) | EISAI PRESENTS NEW LEQEMBI® (LECANEMAB-IRMB) INVESTIGATIONAL SUBCUTANEOUS FORMULATION INTERIM STUDY RESULTS AND CLINICAL IMPROVEMENT DATA IN EARLIER STAGES OF EARLY ALZHEIMER'S DISEASE FROM ADDITIONAL ANALYSES OF CLARITY AD AT THE CLINICAL TRIALS ON ALZHE | NASDAQ:BIIB | Biogen Inc |
25/10/2023 | 16:51 | GlobeNewswire Inc. | New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer’s Disease | NASDAQ:BIIB | Biogen Inc |
24/10/2023 | 15:30 | PR Newswire (US) | LEQEMBI® (lecanemab-irmb) NAMED ONE OF TIME's BEST INVENTIONS OF 2023 | NASDAQ:BIIB | Biogen Inc |
19/10/2023 | 13:30 | GlobeNewswire Inc. | Biogen to Present New Data at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Meeting | NASDAQ:BIIB | Biogen Inc |
04/10/2023 | 14:15 | IH Market News | Keep An Eye Out: Pre-Market Movers And Recommendations | NASDAQ:BIIB | Biogen Inc |
29/09/2023 | 22:49 | Dow Jones News | Biogen's Tofidence Intravenous Formulation Gets FDA Approval | NASDAQ:BIIB | Biogen Inc |
29/09/2023 | 22:06 | GlobeNewswire Inc. | FDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA® | NASDAQ:BIIB | Biogen Inc |
28/09/2023 | 23:25 | Edgar (US Regulatory) | Form 8-K/A - Current report: [Amend] | NASDAQ:BIIB | Biogen Inc |
26/09/2023 | 14:59 | GlobeNewswire Inc. | Biogen Completes Acquisition of Reata Pharmaceuticals | NASDAQ:BIIB | Biogen Inc |
25/09/2023 | 07:02 | GlobeNewswire Inc. | LEQEMBI® Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Japan | NASDAQ:BIIB | Biogen Inc |